AbbVie Inc.
NYSE:ABBVDrug Manufacturers - General
-$4.65 today
- Market cap
- $505.47B
- Beta
- 0.31
- P/E (TTM)
- 105.6
- EPS (TTM)
- $2.05
- Dividend yield
- 3.11%
Volume 4.73M
Average 6.47M
ABBV Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
AbbVie Inc.NYSE: ABBV
Net Debt · Q2 FY2026 · quarter ended Jun 2026
Net debt broadly unchanged from a year ago
Net debt stood at $64.25B at the end of Q2 FY2026, up 0.4% from a year earlier and up 1.2% from the prior quarter. Over 3 fiscal years it compounded at +5.1% a year.
Context
- Net debt amounted to 47.5% of total assets at the end of Q2 FY2026, up 0.9 pp from a year earlier.
- Net debt increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +0.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- 63.84B USD
- Year-over-year change
- +2.4%
- 4-year CAGR
- -1.5%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 63.84B | +2.4% |
| FY2024 | 2024-12-31 | 62.32B | +31.7% |
| FY2023 | 2023-12-31 | 47.31B | -14.0% |
| FY2022 | 2022-12-31 | 54.99B | -18.9% |
| FY2021 | 2021-12-31 | 67.83B | — |
Net Debt vs competitors
How ABBV compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +0.4% is the 7th highest of 10, against a peer median of +3.4%.
- Net debt amounts to 47.5% of total assets for ABBV, versus a peer median of 32.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $64.25B USD | +0.4% | +5.1% | 47.5% | |
| Jun 2026 | $62.22B USD | +3.4% | +24.4% | 30.9% | |
| Jun 2026 | $47.06B USD | +71.8% | +23.1% | 36.3% | |
| Jun 2026 | $46.02B USD | +26.0% | +35.6% | 32.3% | |
| Jun 2026 | $43.32B USD | -10.1% | +13.2% | 45.3% | |
| Jun 2026 | $41.4B USD | +59.3% | +7.9% | 33.9% | |
| Jun 2026 | $34.4B USD | -10.3% | +5.3% | 39.3% | |
| Sep 2026 | $27.74B USD | +0.6% | +1.8% | 14.1% | |
| Sep 2026 | $26.21B USD | +6.9% | +1.5% | 21.9% | |
| Jun 2026 | £15.04B GBP | -20.2% | -6.1% | 24.5% | |
| Peer median (excluding ABBV) | — | +3.4% | +7.9% | 32.3% | |
Competitors are the stored peer set for ABBV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 9.75B | 9.2B | 12.81B | 5.52B | 5.23B |
| Short-term Investments | 84M | 28M | 2M | 31M | 28M |
| Net Receivables | 9.98B | 11.25B | 11.16B | 10.92B | 12.59B |
| Inventory | 3.13B | 3.58B | 4.1B | 4.18B | 4.95B |
| Other Current Assets | 226M | 4.4B | 4.93B | 4.93B | 6.27B |
| Total Current Assets | 27.93B | 28.46B | 33B | 25.58B | 29.06B |
| Property, Plant & Equipment (Net) | 5.11B | 4.94B | 4.99B | 5.13B | 6.37B |
| Goodwill | 32.38B | 32.16B | 32.29B | 34.96B | 35.64B |
| Intangible Assets | 75.95B | 67.44B | 55.61B | 60.07B | 52.64B |
| Long-term Investments | 277M | 241M | 304M | 279M | 299M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 4.88B | 5.57B | 8.51B | 9.14B | 9.95B |
| Total Non-current Assets | 118.6B | 110.34B | 101.71B | 109.58B | 104.9B |
| Total Assets | 146.53B | 138.81B | 134.71B | 135.16B | 133.96B |
| Account Payables | 2.88B | 2.93B | 3.69B | 2.95B | 3.59B |
| Short-term Debt | 12.67B | 4.3B | 7.19B | 6.8B | 8.75B |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 17.85B | 20.93B | 25.16B | 27.01B | 25.63B |
| Total Current Liabilities | 35.19B | 29.54B | 37.84B | 38.75B | 43.29B |
| Long-term Debt | 64.16B | 59.12B | 52.17B | 60.34B | 59.61B |
| Deferred Tax Liabilities | 8.98B | 8.69B | 8.63B | 7.63B | 7.96B |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 22.02B | 23.4B | 24.91B | 24.38B | 25.62B |
| Total Non-current Liabilities | 95.9B | 91.98B | 86.47B | 93.05B | 93.9B |
| Total Liabilities | 131.09B | 121.52B | 124.31B | 131.8B | 137.19B |
| Common Stock | 18M | 18M | 18M | 18M | 18M |
| Retained Earnings | 3.13B | 4.78B | (1B) | (7.9B) | (15.49B) |
| Accumulated OCI | (2.9B) | (2.2B) | (2.31B) | (1.93B) | (1.14B) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 28M | 33M | 37M | 39M | 42M |
| Total Equity | 15.44B | 17.29B | 10.4B | 3.36B | (3.23B) |
| Total Debt | 77.58B | 64.19B | 60.12B | 67.84B | 69.07B |
| Net Debt | 67.83B | 54.99B | 47.31B | 62.32B | 63.84B |
AbbVie Inc.
NYSE:ABBV
Intrinsic Alpha fair value
Locked
Current Price
$285.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.